[{"data":1,"prerenderedAt":195},["ShallowReactive",2],{"drug-valbenazine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":19,"regimens":50,"contraindications":89,"warnings":99,"renal":114,"monitoring":115,"interactions":116,"review":117,"examples":120,"atc":131,"iran":133,"usApproval":140,"links":146,"populations":160},"valbenazine",1,{"fa":7,"en":8},"والبنازین","Valbenazine","nervous-system",{"fa":11,"en":12},"مهارکننده VMAT2","VMAT2 inhibitor",[14],{"name":15,"market":16},"Ingrezza","US",[18,7],"ingrezza",[20,34,42],{"id":21,"form":22,"route":23,"label":24,"concentration":25,"markets":29,"refs":30},"cap-40","capsule","oral","40 mg capsule",{"amount":26,"unit":27,"perUnit":22,"scored":28},40,"mg",false,[16],[31],{"source":32,"section":33},"fda-ingrezza","3",{"id":35,"form":22,"route":23,"label":36,"concentration":37,"markets":39,"refs":40},"cap-60","60 mg capsule",{"amount":38,"unit":27,"perUnit":22,"scored":28},60,[16],[41],{"source":32,"section":33},{"id":43,"form":22,"route":23,"label":44,"concentration":45,"markets":47,"refs":48},"cap-80","80 mg capsule",{"amount":46,"unit":27,"perUnit":22,"scored":28},80,[16],[49],{"source":32,"section":33},[51,75],{"id":52,"disease":53,"label":54,"population":57,"type":61,"unit":27,"dose":62,"refs":65,"notes":68},"td","tardive-dyskinesia",{"fa":55,"en":56},"دیسکینزی دیررس — ۴۰ mg یک بار در روز، پس از یک هفته ۸۰ mg","Tardive dyskinesia — 40 mg once daily, 80 mg after one week",{"minAge":58},{"value":59,"unit":60},18,"year","titration",{"dividedDoses":5,"titration":63},{"start":26,"increment":26,"incrementEveryDays":64,"max":46},7,[66],{"source":32,"section":67},"2.1",[69],{"text":70,"refs":73},{"fa":71,"en":72},"۴۰ یا ۶۰ mg هم بسته به پاسخ و تحمل ممکن است.","40 or 60 mg may be considered depending on response and tolerability.",[74],{"source":32,"section":67},{"id":76,"disease":77,"label":78,"population":81,"type":61,"unit":27,"dose":83,"refs":87},"hd","huntington-chorea",{"fa":79,"en":80},"کره هانتینگتون — ۴۰ mg یک بار در روز، هر ۲ هفته ۲۰ mg بیشتر تا ۸۰ mg","Huntington chorea — 40 mg once daily, +20 mg every 2 weeks to 80 mg",{"minAge":82},{"value":59,"unit":60},{"dividedDoses":5,"titration":84},{"start":26,"increment":85,"incrementEveryDays":86,"max":46},20,14,[88],{"source":32,"section":67},[90],{"id":91,"severity":92,"text":93,"refs":96},"hyper","block",{"fa":94,"en":95},"سابقه حساسیت به والبنازین (کهیر، آنژیوادم).","History of hypersensitivity to valbenazine (rash, urticaria, angioedema).",[97],{"source":32,"section":98},"4",[100,107],{"text":101,"refs":104},{"fa":102,"en":103},"هشدار جعبه‌ای: افسردگی و افکار خودکشی در بیماری هانتینگتون؛ در افسردگی درمان‌نشده یا افکار خودکشی ممنوع.","Boxed warning: depression and suicidality in Huntington’s disease; contraindicated with untreated depression or suicidality.",[105],{"source":32,"section":106},"Boxed Warning",{"text":108,"refs":111},{"fa":109,"en":110},"خواب‌آلودگی؛ طولانی شدن QT؛ سندرم نورولپتیک بدخیم؛ پارکینسونیسم.","Somnolence; QT prolongation; neuroleptic malignant syndrome; parkinsonism.",[112],{"source":32,"section":113},"5",[],[],[],{"status":118,"reviewer":119,"date":119},"unverified",null,[121,126],{"regimen":52,"formulation":21,"input":122,"expect":125},{"ageYears":123,"weightKg":124},55,75,{"perDose":26,"tabletsPerDoseRounded":5},{"regimen":76,"formulation":21,"input":127,"expect":130},{"ageYears":128,"weightKg":129},45,70,{"perDose":26,"tabletsPerDoseRounded":5},[132],"N07XX13",{"status":134,"refs":135},"not-found",[136],{"source":137,"section":138,"url":139},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Valbenazine",{"kind":141,"refs":142,"id":145},"NDA",[143],{"source":32,"section":144},"SPL approval \u002F marketing category","NDA209241",[147,150,154,157],{"kind":148,"url":149,"label":145},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=209241",{"kind":151,"url":152,"label":153},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=4c970164-cafb-421f-9eb5-c226ef0a3417","FDA Ingrezza",{"kind":155,"url":156,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa617023.html",{"kind":158,"url":159,"label":132},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N07XX13",{"pregnancy":161,"lactation":170,"pediatric":178,"geriatric":186},{"level":162,"text":163,"quote":166,"refs":167},"caution",{"fa":164,"en":165},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited available data on INGREZZA or INGREZZA SPRINKLE use in pregnant women are insufficient to inform a drug-associated risk.",[168],{"source":32,"section":169},"8.1",{"level":162,"text":171,"quote":174,"refs":175},{"fa":172,"en":173},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of valbenazine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.",[176],{"source":32,"section":177},"8.2",{"level":162,"text":179,"quote":182,"refs":183},{"fa":180,"en":181},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of INGREZZA and INGREZZA SPRINKLE have not been established in pediatric patients.",[184],{"source":32,"section":185},"8.4",{"level":187,"text":188,"quote":191,"refs":192},"ok",{"fa":189,"en":190},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dose adjustment of INGREZZA or INGREZZA SPRINKLE is required for elderly patients.",[193],{"source":32,"section":194},"8.5",1792156199000]